Leukemia Research
Volume 29, Issue 2 , Pages 159-163 , February 2005

Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection

  • Alessandro Corso

      Affiliations

    • Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy
    • Corresponding Author InformationCorresponding author. Fax: +34 382 502250.
    • ,
  • Marzia Varettoni

      Affiliations

    • Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy
    • ,
  • Silvia Mangiacavalli

      Affiliations

    • Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy
    • ,
  • Patrizia Zappasodi

      Affiliations

    • Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy
    • ,
  • Catherine Klersy

      Affiliations

    • Division of Biometry and Clinical Epidemiology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy
    • ,
  • Chiara Rusconi

      Affiliations

    • Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy
    • ,
  • Emile Colucci

      Affiliations

    • Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy
    • ,
  • Angela Lorenzi

      Affiliations

    • Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy
    • ,
  • Daniela Troletti

      Affiliations

    • Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy
    • ,
  • Erica Consensi

      Affiliations

    • Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy
    • ,
  • Mario Lazzarino

      Affiliations

    • Division of Hematology, IRCCS Policlinico San Matteo, University of Pavia, Via Golgi 2, 27100 Pavia, Italy

Received 26 April 2004 ,Accepted 10 May 2004.

References 

  1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91–97
  2. Barlogie B, Jagannath S, Vesole D, et al. Superiority of tandem autologous transplantation over standard therapy of previously untreated multiple myeloma. Blood. 1997;89:789–793
  3. Shipp MA, Abeloff MD, Antman KH, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphomas: report of the jury. J Clin Oncol. 1999;17:423–429
  4. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998;351:700–708
  5. Gratwohl A, Passweg J, Baldomero H, Hermans J. Blood and marrow transplantation activity in Europe 1997: European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1999;24:231
  6. Bensinger WI, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol. 1995;13:2547–2555
  7. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86:3961–3969
  8. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood. 1995;85:588–596
  9. Perez-Simon JA, Martin A, Caballero D, et al. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24:1279–1283
  10. Scheid C, Draube A, Reiser M, et al. Using at least 5 × 106kg−1 CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant. 1999;23(1):9–13
  11. Lefrère F, Delarue R, Somme D, et al. High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose. Transfusion. 2002;42:443–450
  12. Corso A, Caberlon S, Pagnucco G, et al. Blood stem cell collection in multiple myeloma: definition of a scoring system. Bone Marrow Transplant. 2000;26:283–286
  13. Corso A, Arcaini L, Caberlon S, et al. A combination of dexamethasone, cyclophosphamide, etoposide and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica. 2002;87:1041–1045
  14. Gandhi MK, Jestice K, Scott MA, et al. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant. 1999;23:9–13
  15. Demirer T, Buknener CD, Gooley T, et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant. 1996;17:937–941
  16. Drake M, Ranaghan L, Morris TCM, et al. Analysis of the effects of prior therapy on progenitor cell yield: use of a chemotherapy score system. Br J Haematol. 1997;98:745–749
  17. Haas R, Mőhle R, Frőhauf S, et al. Patients characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 1994;83:3787–3794
  18. Ketterer N, Salles G, Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol. 1998;103:235–242
  19. Perea G, Sureda A, Martino R, et al. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol. 2001;80:592–597
  20. Canales MA, Fernánde-Jimènez MC, Martìn A, et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin’s disease. Haematologica. 2001;86:494–498
  21. Fruehauf S, Haas R, Conradt C, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state hemtopoiesis allow to estimate the yield of mobilized PBPC after Filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood. 1995;85:2619–2626
  22. Osma MM, Ortuño F, de Arriba F, et al. Bone marrow steady-state CD34+/CD71− cell content is a predictive value of rG-CSF-mobilized CD34+ cells. Blood. 1998;21:983–985
  23. Van Putten LM, Lelieveld P, Kram-Idsenga LK. Cell-cycle specificity and therapeutic effectiveness of cytostatic agents. Cancer Chemother Rep. 1972;56(6):691–700
  24. Corso A, Lorenzi A, Zappasodi P, et al. Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma. Haematologica. 2003;88(8):958–960

PII: S0145-2126(04)00232-2

doi: 10.1016/j.leukres.2004.05.018

Leukemia Research
Volume 29, Issue 2 , Pages 159-163 , February 2005

Article Tools